EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors

Table 4 Treatment patterns among patients with metastatic NSCLC with a subsequent therapy

Subsequent therapy	Patients who received 1 L EGFR-TKI and had subsequent therapy	Patients who received 2 L+ EGFR-TKI and had subsequent therapy
Subsequent therapy	(N = 160)	(N = 134)
Chemotherapy alone, n (%)	25 (15.6)	29 (21.6)
Immunotherapy alone, n (%)	22 (13.8)	55 (41.0)
Targeted therapies n (%)^a	112 (70.0)	49 (36.6)
EGFR-TKI^b	102 (63.8)	33 (24.6)
Continued on/switched to another 1st/2nd gen. EGFR-TKI	62 (38.8)	27 (20.1)
Afatinib	33 (20.6)	11 (8.2)
Erlotinib	17 (10.6)	13 (9.7)
Gefitinib	13 (8.1)	5 (3.7)
Osimertinib^c	40 (25.0)	7 (5.2)
Other targeted therapies^d	10 (6.3)	16 (11.9)
Clinical study drug, n (%)	1 (0.6)	1 (0.7)

1 L first line, 2 L+ second or later line, ALK anaplastic lymphoma kinase EGFR epidermal growth factor receptor, EGFR-TKI epidermal growth factor receptor-tyrosine kinase inhibitor, NSCLC non-small cell lung cancer
^a Patients could have received targeted therapies alone or in combination with chemotherapy and/or immunotherapy
^b Four patients had more than one EGFR-TKI as a subsequent therapy. Hence, the sum of the individual EGFR-TKIs (i.e. afatinib, erlotinib, geftinib, and osimertinib) will be greater than the total number who received EGFR-TKI
^c Of the 47 patients who received osimertinib as subsequent therapies, 24 were tested T790M positive, seven were not positive for T790M, and 16 were not tested for EGFR mutations
^d Other targeted therapeutic agents are listed in Table 1

ISSN: 1471-2407